{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:28:02Z","timestamp":1793744882529,"version":"4.6.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.gore.2026.102205","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:32:13Z","timestamp":1789169533000},"page":"102205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["HER2-directed therapy with Trastuzumab deruxtecan in recurrent mucinous ovarian carcinoma: complete clinical response and response to rechallenge"],"prefix":"10.1016","volume":"67","author":[{"given":"Oriana","family":"Krivenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.gore.2026.102205_bb0005","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdq257","article-title":"Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience","volume":"21","author":"Alexandre","year":"2010","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102205_bb0010","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1186\/s12885-024-13226-1","article-title":"Real-world evidence of Trastuzumab Deruxtecan (T-DXd) efficacy in HER2-expressing gynecological malignancies","volume":"24","author":"Andrikopoulou","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.gore.2026.102205_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10010052","article-title":"Mucinous cancer of the ovary: overview and current status","volume":"10","author":"Babaier","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.gore.2026.102205_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-203361","article-title":"Trismus and diffuse polymyalgia: an unusual presentation of recurrent metastatic ovarian cancer","volume":"2014","author":"Benjamin","year":"2014","journal-title":"BMJ Case Rep."},{"issue":"5","key":"10.1016\/j.gore.2026.102205_bb0025","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.fertnstert.2015.06.008","article-title":"Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients","volume":"104","author":"Bentivegna","year":"2015","journal-title":"Fertil. Steril."},{"issue":"5","key":"10.1016\/j.gore.2026.102205_bb0030","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102205_bb0035","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-018-0464-2","article-title":"Comparison of stage III mucinous and serous ovarian cancer: a case-control study","volume":"11","author":"Firat Cuylan","year":"2018","journal-title":"J. Ovarian Res."},{"issue":"3","key":"10.1016\/j.gore.2026.102205_bb0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2010.02.010","article-title":"Unmasking the complexities of mucinous ovarian carcinoma","volume":"117","author":"Frumovitz","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2026.102205_bb0045","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s43032-023-01443-1","volume":"31","author":"Gao","year":"2024","journal-title":"Reprod. Sci."},{"issue":"3","key":"10.1016\/j.gore.2026.102205_bb0050","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ygyno.2019.03.256","article-title":"An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC\/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor","volume":"153","author":"Gore","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102205_bb0055","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ygyno.2019.12.015","article-title":"Therapeutic options for mucinous ovarian carcinoma","volume":"156","author":"Gorringe","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102205_bb0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/IGC.0000000000001202","article-title":"Characteristics and prognosis of stage I ovarian mucinous tumors according to Expansile or infiltrative type","volume":"28","author":"Gouy","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.gore.2026.102205_bb0065","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2004.08.078","article-title":"Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment","volume":"22","author":"Hess","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.gore.2026.102205_bb0070","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.6004\/jnccn.2012.0113","article-title":"Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location","volume":"10","author":"Jain","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"11","key":"10.1016\/j.gore.2026.102205_bb0075","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(11)70058-4","article-title":"Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma","volume":"12","author":"Kelemen","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.gore.2026.102205_bb0080","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-9-433","article-title":"HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","volume":"9","author":"McAlpine","year":"2009","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.gore.2026.102205_bb0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.gore.2026.102205_bb0090","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMra1813254","article-title":"Mucinous Ovarian Carcinoma","volume":"380","author":"Morice","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.gore.2026.102205_bb0095","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.ejca.2012.12.004","article-title":"Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases","volume":"49","author":"Muyldermans","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.gore.2026.102205_bb0100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest Research and Development into the antibody-drug conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem. Pharm. Bull. (Tokyo)."},{"issue":"2","key":"10.1016\/j.gore.2026.102205_bb0105","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2004.12.056","article-title":"Advanced stage mucinous epithelial ovarian cancer: the Hellenic cooperative oncology group experience","volume":"97","author":"Pectasides","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102205_bb0110","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.breast.2022.10.008","article-title":"Trastuzumab-based regimens beyond progression: a crucial treatment option for HER2+ advanced\/metastatic breast cancer","volume":"66","author":"Sanglier","year":"2022","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.gore.2026.102205_bb0115","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/00000478-200307000-00014","article-title":"Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis","volume":"27","author":"Seidman","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.gore.2026.102205_bb0120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ygyno.2009.02.010","article-title":"Clinicopathological characteristics of mucinous adenocarcinoma of the ovary","volume":"113","author":"Shimada","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2026.102205_bb0125","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cam4.5021","article-title":"Breast cancer brain metastasis: current evidence and future directions","volume":"12","author":"Sun","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.gore.2026.102205_bb0130","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1200\/GO.21.00085","article-title":"Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline","volume":"7","author":"Vanderpuye","year":"2021","journal-title":"JCO Glob. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102205_bb0135","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.25460","article-title":"Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a gynecologic oncology group study","volume":"117","author":"Zaino","year":"2011","journal-title":"Cancer"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:01:22Z","timestamp":1793743282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926001852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"alternative-id":["S2352578926001852"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102205","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2-directed therapy with Trastuzumab deruxtecan in recurrent mucinous ovarian carcinoma: complete clinical response and response to rechallenge","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102205","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102205"}}